SOLTF
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 19.17 | $11.3B | -$2.0B |
| 2025 Q4 | -86.27 | $7.8B | -$272M |
| 2025 Q3 | -18.01 | $6.9B | -$3.1B |
| 2025 Q2 | -26.35 | $8.4B | -$270M |
| 2025 Q1 | -8.45 | $6.6B | $504M |
| 2024 Q4 | -14.85 | $6.9B | -$11.1B |
| 2024 Q3 | 13.35 | $9.3B | $1.5B |
| 2024 Q2 | -15.86 | $8.1B | $3.7B |